Notice of Proposed Sale · 144
NovaBridge Biosciences
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- NovaBridge Biosciences
- Issuer CIK
- 0001778016
- SEC file number
- 001-39173
- Phone
- (301) 670 2800
- Person for whose account securities are to be sold
- Dennis Phillip Andrew
- Relationships to issuer
- Chief Medical Officer
- Street
- SUITE 400, 2440 RESEARCH BLVD
- City
- ROCKVILLE
- State / country code
- MD
- Postal code
- 20850
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 3,569 | 5,798.55 | 265,377,891 | 09/18/2026 | NASDAQ | Citigroup Global Markets, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- Citigroup Global Markets, Inc.
- Street
- 390 Greenwich St.
- City
- New York
- State / country code
- NY
- Postal code
- 10013
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 09/18/2026 | Restricted Stock Vesting | NovaBridge Biosciences | 10,302 | N | 09/18/2026 | Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Dennis Phillip Andrew | Common Stock | 06/18/2026 | 3,693 | 5,593.05 |
Seller — prior-sale row 1, entry 1
- Name
- Dennis Phillip Andrew
- Street
- SUITE 400, 2440 RESEARCH BLVD
- City
- Rockville
- State / country code
- MD
- Postal code
- 20850
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
Shares to be sold were from the vesting of the restricted stock units to cover tax obligations. .
Notice signature
- Notice date
- 09/18/2026
- Signed
- CONFORMED SIGNATURE ON FILE
Company context
NovaBridge Biosciences ("NovaBridge") (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program. NovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye.